

COMMENTARY

The Fund returned 1.05% for the month of January 2025. Net exposure averaged 33% long, while gross averaged 102%. This brings the since inception return to 18.48% p.a. net of fees.

Gains through the month of January, were generated from the long themes in Aerospace (+84 bps) and Data is the New Oil (+57 bps). With losses primarily concentrated for the month from our Uranium theme (-37 bps).

Generally, Arnott prefers to enter early with ideas. Not only do these opportunities provide considerable upside, they also typically have less downside. There are other opportunities however, that arise, that allows Arnott to achieve asymmetric returns without being at the very early stages. As an investment trend emerges, stock prices may get ahead of themselves and then disappoint. While the underlying investment trend remains intact, the share price suffers wild swings up and down. Arnott has recently initiated such a position in the incumbent GLP-1 producers.


[Obesity rates in the United States](#) declined year-on-year for the first time since the turn of millennia last year. Interestingly, this trend change comes at a point in time when glucagon like receptor drugs ('GLP-1's') have accelerated in their adoption following the blockbuster release of Wegovy in 2022. Coming from a near standing start, the GLP-1 drug category is forecast to generate greater than US\$100 bn in annual sales by 2030 as GLP-1 drug adoption accelerates in the fight against obesity as well as heart disease, kidney disease, sleep apnoea and other chronic conditions currently undergoing trials for their medical benefit. With the emergence of GLP-1 drugs, Arnott believes that we are undergoing a reframing of obesity as a chronic condition rather than an aesthetic concern, reframing both societal and medical approaches to obesity.

STRATEGY PERFORMANCE METRICS*

From May 2013

Annualised returns	18.48%
% Positive months	62.14%
Average monthly return	1.48%
Average return in MSCI up months	1.30%
Average return in MSCI down months	1.80%
Best month	13.07%
Worst month	-6.09%
Largest drawdown	-11.61%
Longest drawdown (mths)	24
Sortino	3.72
Sharpe ratio	1.52

THEME CONTRIBUTORS TO FUND PERFORMANCE ^*



^ Theme Contributors to Performance is Gross of Fees and exclusive of Cash.

CORRELATION TO ASSETS - STRATEGY*

Global Equity Markets	0.04
US\$ Gold	0.01
Bloomberg Commodities Index	0.00
Hedge Fund L/S	0.02

MONTHLY SUMMARY METRICS - JANUARY 2025

NET RETURN	AV GROSS EXP	AV NET EXP
1.05%	102%	33%

STRATEGY HISTORICAL PERFORMANCE (%)

	Jan	Feb	Mar	Apr	May	Jun	Jul	Aug	Sep	Oct	Nov	Dec	Annual
2013						13.07	7.63	2.97	2.82	-2.69	5.23	-5.25	25.00
2014	7.61	6.56	2.43	0.77	8.87	-0.93	8.46	-3.78	0.34	7.78	3.24	1.92	51.59
2015	4.46	2.88	1.99	3.19	4.12	-0.52	3.44	11.47	5.23	0.00	3.67	5.72	55.80
2016	-6.09	2.14	-5.17	-2.83	3.30	0.40	2.69	7.49	6.29	-1.15	-2.34	0.48	4.33
2017	7.99	-4.01	-2.94	-0.34	0.43	4.08	4.21	-0.02	3.37	2.79	-2.32	5.51	19.58
2018	3.47	0.88	0.72	-1.68	-1.86	0.09	0.03	0.66	1.24	-0.18	-2.61	-0.50	0.12
2019	-1.66	0.53	-0.30	-1.16	-1.90	0.29	1.70	1.72	-2.10	-2.04	3.20	1.05	-0.82
2020	-1.90	-4.03	6.32	8.76	1.82	-1.47	2.69	3.82	-2.94	-3.32	8.59	7.22	27.23
2021	3.26	5.69	2.74	3.93	5.03	-0.40	-2.81	5.60	5.75	1.30	5.37	-0.24	40.90
2022	2.07	-0.34	-1.10	0.95	2.50	-1.68	-1.61	4.48	-1.55	-3.07	-0.77	1.87	1.50
2023	-0.29	-2.34	-0.36	-0.75	1.07	2.02	0.88	1.58	2.45	-2.70	-0.24	3.16	4.40
2024	1.10	-1.53	3.45	1.37	0.78	-0.67	-3.36	-1.93	3.45	0.70	-0.54	0.46	3.00
2025	1.05												1.05

Past performance is not an indicator of future performance.

* Strategy - refers to the period from 2013 - 2017 for Bondi Capital Investments Pty Ltd ('Managed Account'), and 2018 - 2024 is for the Fund. The Managed Account was externally administered by Apex, but not externally audited. The Fund is audited by EY. Performance for the whole reported period is reported net of all fees. The currency is AUD.

Above data and fees apply to the Arnott Opportunities Trust - Founder Class. Other classes will be subjected to different fees. For a copy of the Information Memorandum, please contact investor relations at investor@arnott.com.au.

COMMENTARY CONTINUED

This shift in obesity trends, along with its knock-on effects, forms the foundation of our Longevity theme. These far-reaching implications have opened opportunities on both the long and short sides of the portfolio, resulting in both winners and losers.


The first order winners Arnott sees is the incumbent GLP-1 drug producers Novo Nordisk and Eli Lilly, which Arnott believes will remain the two dominant players in this blockbuster drug category.

In Arnott’s view, the losers are broad reaching but the implementation at the moment has focused on companies that are most impacted from reduced caloric intake spanning industries such as snacks, beverages, alcohol and other delicacies.

Arnott believes that this is the early innings of this change and is excited about continuing to develop the pipeline of ideas deployed within this theme on both the long and short side.

STRATEGY NET AND GROSS HISTORICAL EXPOSURE*

Net and Gross Exposure



INVESTMENT STRATEGY

The Fund adopts an absolute return strategy, focusing on thematic investment opportunities with an equity bias. We seek to achieve the investment objective through our asymmetric investment approach which includes:

1. Finding what we perceive to be good quality investments based on our analysis; and
2. Not losing money in the pursuit of realising these investments.

We strive to achieve asymmetric returns through a thematic investment process. This has four pillars.

1. Find asymmetric themes;
2. Invest in the best ideas within those themes;
3. Focus on macro drivers for risk & opportunities; and
4. Generate an asymmetric return profile.

FUND INFORMATION

BASE CURRENCY	AUD	ARNOTT CAPITAL PTY LTD	AFSL License 233743 ABN 23086081889
STRATEGY INCEPTION	1999	CONTACT DETAILS	investor@arnott.com.au
MINIMUM SUBSCRIPTIONS	AUD \$100,000	WITHDRAWALS	Monthly
FUND ADMINISTRATOR	Apex Group Ltd.	PRIME BROKER	Morgan Stanley International PLC
LEGAL ADVISORS	Ernst and Young	FUND AUDITOR	Ernst and Young
FEE STRUCTURE	Management Fee	Performance Fee	Subscriptions
Founder Class	0%	25%	Closed to new investors
Main - Post July 2020 Class	1.5%	20%	Monthly

All data displayed in this document is Founder Class data. For a copy of the Offering Memorandum, please contact investor relations at investor@arnott.com.au.

Disclaimer

This document is for wholesale clients only (as defined in the Corporations Act 2001 (Cth)) and has been prepared by the appointed Investment Manager, Arnott Capital Pty Limited (ABN 23 086 081 889, AFSL 233743) ('Arnott', we, us, our). Channel Investment Management Limited ACN 163 234 240 AFSL 439007 ('CIML') is the trustee and issuer of units in the Arnott Opportunities Trust (the 'Fund'). Channel Capital Pty Ltd ACN 162 591 568 Authorised Representative No. 001274413 ('Channel Capital') provides investment infrastructure and distribution services for Arnott and is the holding company of CIML. This document is supplied on the following conditions which are expressly accepted and agreed to by each interested party ('Recipient').

By viewing this document, you are representing that you are a wholesale client and agree to keep this document confidential. This document is directed at persons who are sophisticated investors with sufficient professional or other experience to properly assess the nature of the matter discussed herein. This document has been prepared for general information purposes only without taking into account any potential investors' personal objectives, financial situation or needs. It should not be relied upon by the recipient in making an investment decision. You should obtain relevant and specific professional advice and check the accuracy of all relevant information before making any investment decision. This document is intended to provide a general outline only and is not intended to be a definitive statement on the subject matter. The document is not intended to be relied upon by recipients given the contingent nature of the content matter. This is not an offer to invest in any security or financial product.

Forward-looking information in this document is provided as a general guide only and should not be relied upon as (and is not) an indication of the future performance of any financial products. No representation is made as to future performance or volatility of the financial products. Persons should rely solely upon their own investigations in respect of the subject matter discussed in this document. Past performance information given in this document is given for illustrative purposes only and are as at the date of publication of this material.

No representations or warranties, express or implied, are made as to the accuracy or completeness of the information, opinions and conclusions contained in this document. In preparing these materials, Arnott has relied upon and assumed, without independent verification, the accuracy and completeness of all information available to Arnott. Whilst efforts have been made to ensure the information is correct, no warranty of accuracy or reliability is given, and no responsibility is accepted for errors of omissions. To the maximum extent permitted by law, neither Arnott nor its directors, employees or agents accept any liability for any loss arising in relation to this document. The offer of interests in the Fund will only be made in the offering document for the Fund. For a copy of the Offering Memorandum, please contact investor relations at investor@arnott.com.au.